Home / Compound Database / IGF-1
Growth Axis

IGF-1 Half-Life & Pharmacokinetics

Mecasermin · Increlex · Insulin-like Growth Factor 1

Human PK Study · FDA-Approved (NDA 021839)

IGF-1 (insulin-like growth factor 1) has markedly different pharmacokinetics depending on whether it circulates free or bound to its carrier proteins. Free IGF-1 has a plasma half-life of only approximately 10 minutes,[2] while IGFBP-3-bound IGF-1 in the ternary complex has a half-life of approximately 12–15 hours.[3] Mecasermin (Increlex), the FDA-approved recombinant form, has a terminal SC half-life of approximately 5.8 hours in its target population.[1]

⚠ Boxed Warning: Hypoglycemia
Mecasermin (Increlex) carries a boxed warning for hypoglycemia. IGF-1 binds the insulin receptor with ~1–5% the potency of insulin. Hypoglycemia was reported in ~49% of clinical trial participants. Must be administered immediately before or after a meal or snack. Source: FDA NDA 021839.

Quick Reference

ParameterValueSource
Half-life — free IGF-1~10 minutesGuler et al. 1988[2]
Half-life — IGFBP-3-bound IGF-1~12–15 hoursLe Roith et al. 2001[3]
Half-life — mecasermin SC (Increlex)~5.8 hoursFDA NDA 021839[1]
Tmax (SC)~2 hoursFDA NDA 021839[1]
5× half-lives to clearance~29 hoursDerived from PK data
Standard dosing0.04–0.12 mg/kg SC BID (with food)FDA NDA 021839[1]
Approval indicationSevere primary IGF-1 deficiency (Laron syndrome)FDA NDA 021839
Hypoglycemia incidence~49% in clinical trialsFDA NDA 021839[1]
Approval statusFDA-approved (Rx)NDA 021839
Data QualityHuman PK StudyFDA NDA 021839
Reviewed by: Halflife Labs Medical Review Team  |  Last updated: January 2025  |  Sources: FDA NDA 021839 (Increlex), peer-reviewed PK literature  |  Data grade: Human PK Study / FDA-approved pharmacokinetics

What Is IGF-1 (Mecasermin)?

Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid polypeptide hormone with structural homology to proinsulin. Endogenous IGF-1 is primarily synthesized in the liver in response to growth hormone (GH) stimulation via the JAK2/STAT5 pathway. IGF-1 mediates most of the anabolic and growth-promoting effects of GH by binding the type 1 IGF receptor (IGF1R) and activating PI3K/Akt and MAPK/ERK signaling cascades.

Mecasermin (Increlex, Ipsen, NDA 021839) is recombinant human IGF-1 produced in E. coli and is FDA-approved for the treatment of severe primary IGF-1 deficiency (Laron syndrome — GH receptor mutations causing GH insensitivity) or GH gene deletion with GH-neutralizing antibodies in children. The approved dose is 0.04–0.12 mg/kg SC twice daily, administered immediately before or after a meal to reduce hypoglycemia risk.[1]

How Long Does IGF-1 Stay in Your System?

The pharmacokinetics of IGF-1 are governed by its binding state. The vast majority (~95–99%) of circulating IGF-1 is bound to one of six IGF-binding proteins (IGFBPs), predominantly IGFBP-3. This binding dramatically extends the half-life from ~10 minutes (free) to 12–15 hours in the ternary complex.[3]

When mecasermin is administered subcutaneously without co-administered IGFBP-3, it distributes into endogenous IGFBP pools. The resulting terminal SC half-life of ~5.8 hours reflects this equilibrium. With twice-daily dosing, steady-state IGF-1 levels are achieved within 3–4 days.[1]

Clearance Timeline (SC Mecasermin, t½ = 5.8 h)

Half-Lives ElapsedTime Post-DosePlasma IGF-1 RemainingStatus
1×~5.8 hours50%Active
2×~11.6 hours25%Active
3×~17.4 hours12.5%Declining
4×~23.2 hours6.25%Minimal
5×~29 hours~3%Essentially cleared

Twice-daily dosing maintains sustained IGF-1 elevation. Second dose is given before/after next meal to cover the trough period while managing hypoglycemia risk.

Dosing Implications

The ~5.8 hour SC half-life and the critical hypoglycemia risk dictate the twice-daily dosing strategy with mandatory meal co-administration. The first dose should be given immediately before or after the morning meal, and the second dose before or after the evening meal, creating two IGF-1 peaks separated by approximately 12 hours.[1]

Dose titration should begin at 0.04–0.08 mg/kg BID and increase by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg BID, based on tolerance and IGF-1 levels monitored approximately 2 hours post-dose (near Tmax). If hypoglycemia occurs and the dose cannot be reduced, a carbohydrate snack must be provided with each injection.

The IGFBP-3-bound half-life (~12–15 hours) is clinically relevant for chronic supplementation: daily IGF-1 administration gradually elevates the endogenous IGFBP-3-bound IGF-1 pool, extending biological exposure beyond the terminal elimination half-life of any single dose.

Pharmacokinetics by Route of Administration

RouteHalf-LifeNotes
Subcutaneous (SC)~5.8 hoursOnly approved route for mecasermin; Tmax ~2 hours
Free IGF-1 (IV)~10 minutesResearch context; extremely rapid clearance
IGFBP-3-bound complex~12–15 hoursEndogenous ternary complex; not a dosing route

Source: FDA NDA 021839; Guler et al. NEJM 1988 (PMID 3287062); Le Roith et al. 2001 (PMID 11159816).

Mechanism of Action

IGF-1 binds with high affinity to the type 1 IGF receptor (IGF1R), a receptor tyrosine kinase. IGF1R autophosphorylation activates the insulin receptor substrate (IRS) family, leading to PI3K/Akt/mTOR activation (anabolic effects: protein synthesis, cell survival, glucose uptake) and Ras/MAPK/ERK activation (mitogenic effects: cell proliferation, differentiation).[3]

IGF-1 also binds the insulin receptor with approximately 1–5% relative affinity, accounting for its significant hypoglycemic potential. At supraphysiological concentrations — such as those achieved with exogenous administration — this cross-reactivity becomes clinically significant, as evidenced by the ~49% hypoglycemia incidence in Increlex trials.[1]

The physiological IGF-1 signal is sustained by IGFBP-3 and ALS acting as a circulating reservoir, slowly releasing free IGF-1 to target tissues. This reservoir function means that the biological effect of both endogenous and exogenous IGF-1 substantially outlasts acute plasma concentration measurements.

In-Class Comparison

CompoundHalf-LifeIGFBP BindingData QualityFDA Status
IGF-1 (Mecasermin)~5.8 h SCNormal (~95–99%)Human PK StudyApproved
IGF-1 LR3~20–30 h (animal)Reduced ~100× vs nativeAnimal StudyNot approved
HGH (Somatropin)~3–4 h SCInduces IGF-1 productionHuman RCTApproved
Gonadorelin~2–10 min IVN/A (peptide hormone)Human PK StudyApproved (Dx)

Track IGF-1 Clearance in Real Time

Halflife Labs models both the mecasermin terminal half-life (~5.8h) and the IGFBP-3-bound reservoir kinetics based on FDA-approved PK data.

Download Free on iOS

Frequently Asked Questions

What is the half-life of IGF-1?
The pharmacokinetics of IGF-1 depend on its binding state. Free IGF-1 has a plasma half-life of approximately 10 minutes (Guler et al. 1988, PMID 3287062). IGFBP-3-bound IGF-1 in the ternary complex has a half-life of approximately 12–15 hours. Mecasermin (Increlex), administered subcutaneously to patients with severe primary IGF-1 deficiency, has a terminal half-life of approximately 5.8 hours per FDA prescribing information (NDA 021839).
Why does IGF-1 have multiple half-lives?
IGF-1 circulates in multiple forms: free (~1–5%, t½ ~10 min), binary IGFBP complexes (variable), and the ternary complex with IGFBP-3 and ALS (~75–80% of total, t½ ~12–15 hours). The ternary complex acts as a circulating reservoir. Mecasermin (rhIGF-1 without co-administered IGFBP-3) equilibrates into endogenous IGFBP pools upon SC injection, producing a terminal SC half-life of ~5.8 hours. Sources: FDA NDA 021839; Le Roith et al. 2001 (PMID 11159816).
What is the hypoglycemia risk with IGF-1?
IGF-1 carries a boxed warning for hypoglycemia. IGF-1 binds the insulin receptor with approximately 1–5% the potency of insulin, and activates glucose uptake through its own IGF1R. In clinical trials of Increlex, hypoglycemia occurred in approximately 49% of patients. The FDA prescribing information (NDA 021839) mandates administration immediately before or after a meal or snack. Insulin co-administration should be avoided without careful monitoring.
How long does IGF-1 (mecasermin) stay in your system?
With a SC half-life of ~5.8 hours, mecasermin plasma concentrations decline to less than 3% of peak by approximately 29 hours (5 half-lives). However, free IGF-1 equilibrates with IGFBP-3 pools, extending the effective biological signal. Twice-daily dosing maintains elevated IGF-1 levels throughout the day, with steady state achieved within 3–4 days. Source: FDA NDA 021839.
What is IGF-1 approved for?
Mecasermin (Increlex) is FDA-approved (NDA 021839) specifically for severe primary IGF-1 deficiency (Laron syndrome — GH receptor mutations) or GH gene deletion with GH-neutralizing antibodies in children. It is not approved for GH deficiency where GH receptors are intact, idiopathic short stature, or performance enhancement. Off-label use carries substantial hypoglycemia risk without adequate safety data for unapproved populations.
What is the difference between IGF-1 and IGF-1 LR3?
Native IGF-1 (mecasermin) has a SC half-life of ~5.8 hours and binds IGFBPs normally (~95–99% bound in circulation). IGF-1 LR3 is a synthetic analog with an N-terminal extension and Arg3 substitution that reduce IGFBP binding approximately 100-fold, extending the estimated functional half-life to ~20–30 hours (animal data only — no human PK study exists). IGF-1 LR3 has no FDA approval. Source: Francis et al., J Mol Endocrinol 1992 (PMID 1390830).
Why is IGF-1 given twice daily?
The twice-daily dosing schedule (0.04–0.12 mg/kg SC BID) is based on the ~5.8 hour terminal half-life and the goal of maintaining supraphysiological IGF-1 concentrations throughout the waking day to drive linear growth in GH-insensitive patients. Once-daily dosing would result in an inadequate trough in the latter half of the day. Food co-administration with each dose is required to manage hypoglycemia risk. Source: FDA NDA 021839.
Does IGFBP-3 affect IGF-1 half-life?
Yes, substantially. IGFBP-3 is the primary circulating carrier of IGF-1, binding ~75–80% of serum IGF-1 in the ternary complex with ALS. This complex extends IGF-1 half-life from ~10 minutes (free) to ~12–15 hours. Mecasermin (Increlex) is rhIGF-1 without co-administered IGFBP-3; its ~5.8 hour SC half-life reflects redistribution into endogenous IGFBP pools. Source: Le Roith et al., Endocr Rev 2001 (PMID 11159816).

References

  1. U.S. Food and Drug Administration. Increlex (mecasermin) Prescribing Information. NDA 021839. FDA AccessData
  2. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987;317(3):137–140. PMID: 3299098
  3. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74. PMID: 11159816
  4. Zapf J, Hauri C, Waldvogel M, et al. Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci USA. 1989;86(10):3813–3817. PMID: 2724452
  5. Ranke MB, Schweizer R, Elmlinger MW, et al. Significance of basal IGF-I, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature in children. Horm Res. 2000;54(2):60–68. PMID: 11174045
  6. World Anti-Doping Agency. 2024 Prohibited List. S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org

Calculate Your IGF-1 Clearance

Halflife Labs models mecasermin SC kinetics and IGFBP-3 reservoir dynamics based on FDA-approved PK parameters.

Open in App